Therapeutic area |
Cardiovascular |
Goal |
1- To further characterize the molecular pharmacology of the CIGB 500 cytoprotective effects toward its clinical use as a cardio-protective and/or cardio-restorative agent.
2- To assess the CIGB500 potential capability to offer hepato-protection in chronic liver damage models. |
Description |
CIGB 500 is a 6 amino acids synthetic peptide with a substantial safety profile. Different experiments conducted by our group have shown that a single pre-conditioning or multiple CIGB 500 administration were able to amplify cellular cytoprotective mechanisms during hepatic and cardiac ischemia / reperfusion episodes in which surgically-relevant times were used. In the rats’ hepatic ischemia study, CIGB500 largely prevented hepatocytes death and transformed the placebo submassive necrotic pattern into a hepatocytes’ individual one – all likely due to attenuation of pro-inflammatory mediators release and by enhancing cellular anti-ROS defense. In a porcine model of acute myocardial infarction, necrosis was reduced by more than 70% as compared to untreated pigs. Further studies using the doxorubicin (DX) induced dilated myocardiopathy rat model proved that CIGB 500 could prevent heart failure and other toxic systemic complications when concomitantly administered to (DX). Independent studies demonstrated that CIGB 500 could restore myocardial damages and failure when therapeutically administered. In both models CIGB 500 significantly reduced lethality. A number of gene involved in CIGB500 orchestrated response have already been identified. In recent models of chronic chemical liver damage in rats, CIGB 500 prevented hepatocyte’s demise and non-parenchymal cells activation and proliferation along both concomitant and therapeutic administration approaches. This opens new avenues for an alternative indication.
|
Patent Status |
Patent granted in Europe and other countries (US). EP 1 354 597 B1 since August 2005.
Patent filed: CU2006-0048. |
Project Status |
A phase I clinical trial is ongoing.
|
Type of collaboration requested |
Corporate partnership for joint development.
|
Competitives advantages Milestones |
This is focused to be the first medication aimed at:
(1) Reduce myocardial infarct extension.
(2) To protect body's epithelial organs against ischemia-reperfusion injury.
(3) To treat hepatic organ failure upon reperfusion damage.
This agent has a large preclinical dossier documenting its safety.
A phase I clinical trial in healthy volunteers is progressing since November 2007. This is a dose scale-up study.
|
Host Insitutions |
Center for Genetic Engineering and Biotechnology (CIGB). Ave 31, e/158 y 190 Cubanacán, Playa. PO Box 6996, La Habana, 10600, Cuba. Tel. (53-7) 2712397; 2716022. Fax. (53-7) 2736008; 2718070. E-mail: ernesto.lopez@cigb.edu.cu
Web site: http://gndp.cigb.edu.cu
|
Project code:
|
BIO/CIGB/2008-13
|
